Gaze Contingent Feedback in Social Anxiety Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Attention Bias Modification Treatment in Social Anxiety

NCT03601377

Social Anxiety

COMPLETED NA

Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety

NCT03346239

Social Anxiety Disorder

COMPLETED NA

Attention Bias Modification Treatment for Children With Social Anxiety

NCT01397032

Social Phobia

COMPLETED PHASE2

Imagery Rescripting and Imaginal Exposure for Social Anxiety: Mechanisms and Outcomes in an Analog Sample

NCT04635904

Social Anxiety

UNKNOWN NA

Statistical Learning as a Predictor of Attention Bias Modification Outcome

NCT03424967

Social Anxiety Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study examines giving social anxious participants gaze-contingent feedback as a novel attention training procedure. Half of the participants will receive contingent feedback while the other half would receive non-contingent "placebo" feedback.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phobia, Social

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gaze-contingent

attention modification: participants will receive gaze-contingent feedback according to their viewing patterns

Group Type ACTIVE_COMPARATOR

attention modification

Intervention Type BEHAVIORAL

participants will receive gaze-continent feedback according to their viewing patterns

non-gaze contingent

Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

participants will receive non-gaze-continent feedback unrelated to their viewing patterns

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

attention modification

participants will receive gaze-continent feedback according to their viewing patterns

Intervention Type BEHAVIORAL

Placebo

participants will receive non-gaze-continent feedback unrelated to their viewing patterns

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A signed consent form
* Men and women between the ages of 18 and 60.
* Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV
* A minimum of a 1-year duration of SP
* SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders
* Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure.

Exclusion Criteria

* Psychotic episode in the past or the present time.
* Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury).
* Another psychotherapeutic treatment during the study.
* Usage of neuroleptic medication.
* Change in medication status during the study.
* Substantial usage of drugs or alcohol in the present time.
* Poor judgment capacity (i.e., children under 18 and special populations).

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No